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Introduction 
 
The amyloid-β precursor protein (APP) is known 
to play a role in the pathogenesis of Alzheimer’s 
disease (AD) as its proteolysis results in the gen-
eration of amyloid-β peptides (Aβ) and muta-
tions in APP cause autosomal dominant early 
onset AD [1].  Aβ can oligomerize and aggregate 
into extracellular deposits of amyloid plaques, a 
classic pathologic hallmark of AD associated 
with perturbed neuronal functions, disrupted 
cellular networks, cell death and tissue degen-
eration [2].  The resulting lesions can have a 
significant impact and dire clinical conse-
quences on cognitive functions in patients.  Un-
fortunately, current therapies for AD remain 
largely symptomatic and disease-modifying 
drugs have yet to be discovered. 
 
Production of Aβ from APP occurs by an amyloi-
dogenic-processing pathway.  First, APP is 
cleaved by β-secretase (also known as the β site 
APP cleaving enzyme (BACE1), or memapsin-2 
[3, 4]) at the extracellular domain to release a 
secreted ectodomain fragment, sAPPβ, and a 
membrane-bound C-terminal fragment, CTFβ or 
C99.  Then, CTFβ is cleaved by -secretase (a 
large multi-subunit complex comprised of prese-
nilin (PS), nicastrin (Nct), anterior pharynx defec-
tive (Aph-1) and the presenilin enhancer (Pen-2) 
[5]) via a process called regulated intramem-
brane proteolysis (RIP).  This results in the pro-
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in AD.  The findings reported here further support that modulation of APP dimerization may be a viable means of re-
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duction of Aβ and an intracellular domain frag-
ment, AICD (APP intracellular domain), which 
can translocate to the nucleus and has been 
implicated in the regulation of gene expression 
[6].  Depending on the location of the -
secretase cleavage, Aβ peptides of 39 to 42 
amino acids are made [7, 8].  In AD, Aβ40 and 
Aβ42 are of most concern, with Aβ42 being the 
most toxic to neurons and synapses.  Alterna-
tively, under non-amyloidogenic condition, APP 
is first cleaved by α-secretase (members include 
the A disintegrin and metalloproteinase pro-
teins, ADAM9, ADAM10 and ADAM17/tumor 
necrosis factor a-converting enzyme (TACE) [9-
11]) to release a truncated ectodomain frag-
ment, sAPPα.  The remaining C-terminal frag-
ment, CTFα or C83, is then cleaved by -
secretase to release a p3 peptide and AICD.  
Most APP molecules undergo this non-
amyloidogenic processing pathway. 
 
APP is a single-pass transmembrane glycopro-
tein with a large extracellular N-terminal domain 
and a short intracellular C-terminal domain.  Its 
structure resembles a cell-surface receptor [12] 
that can bind ligands and participate in protein-
protein interactions.  Like many receptor pro-
teins that dimerize upon ligand activation, APP 
can also form homodimers [12, 13], as well as 
heterodimers with Notch for cellular signaling 
[14-16] and with its homologs the amyloid pre-
cursor like proteins 1 and 2 (APLP1 and 2) for 
cellular adhesion and cell-cell communication 
[17, 18].  The precise function of APP and the 
significance of its dimerization have yet to be 
determined.  However, many biological activities 
have been linked to the protein, including that 
of platelet aggregation [19], metal homeostasis 
[20-22], gene transcription and cellular metabo-
lism [6, 23], and various neuronal processes 
such as cellular growth, differentiation, migra-
tion, aborization, axonal transport, memory for-
mation, and neuroprotection [24-31]. 
 
APP has a few notable dimerization sites.  First, 
the E1 growth factor like domain (GFLD) has 3 
cysteine bridges where the bridge between 
Cys98 and Cys105 forms an important beta 
hairpin loop for dimerization [32].  Secondly, the 
residues His147, His151, Tyr168, and Met170 
at the E1 copper-binding domain (CuBD) form a 
tetrahedral structure that can coordinate metals 
such as copper and zinc that can regulate APP 
dimerization [33, 34].  The E2 collagen-binding 
site (CBD) can bind ligands such as Type I colla-
gen and heparin for cellular adhesion and par-
ticipate in both cis- and trans- APP dimerization 
[35, 36].  Additionally, binding of Aβ to the jux-
tamembrane region facilitates APP multimeriza-
tion, which may be crucial for cell death signal-
ing [37].  Finally, 3 consecutive GxxxG motifs at 
the transmembrane domain (Aβ residues 25-
37) [8], and the GXXXA sequence that comes 
directly after [38], are the most studied sites for 
APP dimerization. 
 
Recent studies suggest that APP dimerization 
may influence Aβ production.  For example, re-
placement of a lysine residue by cysteine at the 
juxtamembrane region of APP (K624C mutant) 
resulted in constitutive APP dimerization via a 
disulphide bond, and a concomitant increase in 
Aβ levels [13].  Likewise, mutations that dis-
rupted the GxxxG transmembrane dimerization 
motif of APP resulted in a corresponding de-
crease of toxic Aβ42 under a ToxR system.  In 
particular, a G33I mutant abolished both dimeri-
zation and Aβ production [8].  However, in a 
follow-up study on GxxxG mutations, it was 
found that increased APP dimerization at the C-
terminal domain by these mutants lead to a 
decrease in Aβ  [39].  Also, when examining 
familial APP mutants that cause early onset AD, 
the mutations destabilized APP transmembrane 
dimerization and increased Aβ42/40 ratio in a 
way that negatively correlated with the mean 
age of onset of AD symptoms [38].  Further-
more, when using an FKBP/rapamycin system 
to examine APP dimerization and its effects on 
Aβ generation in the absence of mutations, it 
was found that induction of dimerization de-
creased Aβ production [40].  Regardless of 
whether APP dimerization increases or de-
creases Aβ, multiple groups report that it does 
have an effect on Aβ levels demonstrating the 
importance of APP dimerization in AD patho-
genesis and that further evaluation of this proc-
ess is warranted. 
 
To better understand the relationship between 
APP dimerization and Aβ production, we devel-
oped an assay to identify small molecule APP 
dimerization inhibitors and subsequently tested 
their effects on Aβ generation.  A high through-
put screen (HTS) was conducted using the 
method of Firefly luciferase enzyme fragment 
complementation (FLuc EFC).  This technique 
has successfully been used by others to study 
epidermal growth factor receptor dimerization 
[41], chemokine receptor dimerization CXCR4 
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and 7 [42], rapamycin induced FRB/FKBP asso-
ciation [43], phospho-dependent association of 
Cdc25C/14-3-3ε in cell cycle division [43], IFN-γ 
induced nuclear translocation of STAT1/STAT1 
complexes [43], cellular marconuclear delivery 
vehicles, [44] as well as protein-protein interac-
tions in plants [45].  Applications of the method 
also allow visualization of luminescence in live 
cells and animals [43, 44].  Here, we applied 
the same principle with the goal of detecting 
APP-APP interactions. Two inactive deletion mu-
tants of the FLuc enzyme were separately fused 
to APP.  When APP is in monomeric form, the 
FLuc fragments remain inactive. However, upon 
APP-APP dimerization, the two inactive FLuc 
fragments are brought in close proximity to form 
a fully functional enzyme. Quantification of APP-
APP interactions is then made possible by 
measuring chemiluminescence following the 
addition of luciferin.  The FLuc EFC is an effec-
tive way to monitor APP-APP interactions that 
could be used for a better understanding of APP 
processing and Aβ production.   
  
Materials and methods 
 
APP-firefly luciferase constructs 
 
Full-length APP Firefly luciferase (APP FLuc FL) 
construct was prepared using a pGL3-basic vec-
tor (Promega) as template.  An AgeI site was 
inserted at the start of the luciferase gene using 
sense (5'–GGC ATT CCG GTA CTG TAC CGG TAG 
CCA CCA TGG AAG AC–3') and anti-sense (5'–
GTC TTC CAT GGT GGC TAC CGG TAC AGT ACC 
GGA ATG CC–3') primers, followed by excision of 
the luciferase insert using the restriction en-
zymes AgeI and XbaI (New England Biolabs).  In 
parallel, an APP YC pcDNA1 plasmid [14] was 
also digested using the same restriction en-
zymes to release the APP pcDNA1 vector. The 
resulting products were then ligated with a 
XbaI/NotI sense (5’–GGC CGA GCT CTG TTA–3’) 
and anti-sense (5’–CTA GTA ACA GAG CTC–3’) 
adapter.   
 
For the construction of the APP firefly luciferase 
N-terminal fragment (APP FLucN) from the APP 
FLuc FL, a stop codon was added after amino 
acid 475 using the sense (5'–GGT CTT CCC GAC 
TAA GAC GCC GGT GAA CTT CCC–3') and anti-
sense (5'–GGG AAG TTC ACC GGC GTC TTA GTC 
GGG AAG ACC–3') primers.   
 
The APP firefly luciferase C-terminal fragment 
(APP FLucC) was constructed by adding an AgeI 
site before amino acid 265 using sense (5'–GAT 
ATG TGG ATT TCG AGT ACC GGT AAT GTA TAG 
ATT TGA AG–3') and anti-sense (5'–CT TCA AAT 
CTA TAC ATT ACC GGT ACT CGA AAT CCA CAT 
ATC-3') primers.  Following that, the DNA encod-
ing for amino acids 1-264 of luciferase was ex-
cised using AgeI, and the remaining plasmid 
was self-ligated.   
 
To make APP Firefly luciferase plasmids suitable 
for stable cell lines, the plasmids in pcDNA1 
vector were cloned into the pcDNA3.1 mammal-
ian expression vector with the geneticin (G418) 
antibiotic resistance gene for eukaryotic cells.  
The APP luciferase insert was excised from the 
pcDNA1 vector using HindII and XbaI.  Likewise, 
the Klotho pcDNA3.1 plasmid [46] was also 
digested with the same enzymes to release the 
Klotho insert.  The resulting enzyme digested 
products were then ligated to create APP FLucN 
and APP FLucC plasmids in pcDNA3.1.  All plas-
mid sequences were confirmed by DNA se-
quencing at Tufts University. 
 
Cell maintenance and transfection  
 
HEK293 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (CellGro) sup-
plemented with 10% fetal bovine serum (FBS) 
(Atlantic Biologicals) and 1% penicillin-
streptomycin (CellGro) at 370C and 5% CO2.  The 
day before transfection, cells were split using 
0.25% Trypsin-EDTA into 6 well plates at a den-
sity of 1x105 cells per well or into 96 well plates 
at a density of 8,000 cells per well.  DNA were 
transfected into cells using Nanofect (Qiagen).  
Forty-eight hours post transfection, cells were 
lysed in lysis buffer (100mM potassium phos-
phate, pH7.8; 0.2% Triton X-100; Complete mini 
protease cocktail inhibitor tablet (Roche)).  Lys-
ates were stored at –80°C until used. 
 
APP-firefly luciferase stably transfected cells 
 
HEK293 cells stably over-expressing APP-Firefly 
luciferase complementing fragments (APP FLuc 
EFC) were made by the limiting dilution method.  
One g each of the APP FLucN and APP FLucC 
plasmids were co-transfected into cells in 10cm 
plates using FugeneHD (Roche).  For selection, 
800mg/mL geneticin (Cellgro) was placed in 
culture medium.  Single cells were grown into 
colonies, and positive clones were assessed for 
optimal protein expression by western blotting 
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and luciferase activity by luminescence assay.   
 
Sodium dodecyl sulphate - polyacrylamide (SDS-
PAGE) electrophoresis and western blotting 
 
Protein concentration in cell lysates was meas-
ured by the Pierce Bicinchoninic Acid (BCA) As-
say in accordance with manufacturer’s protocol.  
Ten g of total protein was denatured in Laem-
mli buffer and separated on 8% Tris-Glycine gels 
at 150V for 60min.  Proteins were then trans-
ferred onto 0.4mm Immobilon Hybridization 
nitrocellulose filter membranes (Millipore). The 
primary and secondary antibodies used are de-
scribed below.  The Supersignal West Pico 
Chemiluminescent Substrate (Thermo scientific) 
was added to the membrane for 5min and the 
blots were then developed on Phoenix Research 
Products F-BX810 Blue X-Ray Films.   
 
Antibodies  
 
Primary antibodies for western blots were 
mouse monoclonal 6E10 (Covance, 1:1000) 
against amino acids 1-17 of Aβ but also recog-
nizing full length APP and sAPPα; rabbit poly-
clonal APP C8 antibody recognizing amino acids 
676-695 of APP for detecting C-terminal frag-
ments (-CTFs), a kind gift from Dr. D. Selkoe 
(1:1000) [47]; mouse monoclonal 192wt (Elan 
Pharmaceuticals, 1:1000) recognizing amino 
acids 590-596 of APP for detecting sAPPb; and 
mouse monoclonal beta-tubulin (Invitrogen, 
1:10,000).  Secondary antibodies used for west-
ern blots were peroxidase labeled goat anti-
mouse IgG (H+L) and peroxidase labeled goat 
anti-rabbit IgG (H+L) (KPL) both at 1:5000.  
 
Aβ enzyme-linked immunosorbent (ELISA) assay 
 
HEK293 cells stably transfected with wtAPP, a 
kind gift from Dr. D. Selkoe, were plated onto 6-
well plates at a density of 4x105 cells per well.  
The next day, 600mL of fresh medium was incu-
bated with cells with 1M of compounds over-
night. Media were then collected and centri-
fuged at 16,873g for 5min at 4°C to discard cell 
debris.  Cell lysates were also prepared, and 
both medium and lysates were stored at -80°C 
until used.  ELISAs were carried out using the 
human Aβ40 and Aβ42 ELISA kits (Invitrogen) in 
accordance with manufacturer’s protocol with 
samples diluted 1:2 in diluent buffer.   
 
Firefly luciferase and dual luciferase reporter 
assay 
 
The luciferase assay used to assess the APP 
FLuc EFC system was carried out using the 
Promega Bright-Glo Luciferase Assay System in 
accordance with manufacturer’s protocol.  One 
hundred L of cell lysate was added to 96 well 
white microtiter plates (Thermo Electron Corpo-
ration), followed by the addition of 100 L sub-
strate, and read immediately in the Promega 
GloMax-Multi microplate reader.  The luciferase 
assay used to assess whether the compounds 
inhibited the luciferase signal was performed 
using the Promega Dual-Luciferase Reporter 
Assay.  Cells in 96-well plates were transfected 
with the SV40 luciferase and TK Renilla plas-
mids (Promega).  The next day, 1M of com-
pound was added to cells.  After 24 hours, lumi-
nescence was measured following substrate 
addition, and the Firefly luciferase signal was 
normalized to the Renilla luciferase signal. 
 
Compound library 
 
The compound library consists of 77,440 small 
molecules that include Food and Drug Admini-
stration (FDA) approved drugs, purified natural 
products, synthetic compound collections from 
Peakdale (High Peak, UK), Maybridge PIc 
(Cornwall, UK), Cerep (Paris, France), Bionet 
Research Ltd. (Cornwall UK), Prestwick (Ilkirsch, 
France), Specs and Biospecs (CP Rijswijk, Neth-
erlands), ENAMINE (Kiev, Ukraine), I.F. Lab LTD 
(Burlington, Ontario Canada), Chemical Diversity 
Labs LTD (San Diego, CA), ChemBridge (San 
Diego, CA), and various academic institutions 
around the world. 
 
High throughput screening (HTS) 
 
Stably transfected cells were maintained in 2-
CellSTACK chambers (Corning) in culture me-
dium (10% FBS, 1% Penicillin/Strptomycin, 
800mg/mL geneticin, in phenol red DMEM) at 
37°C and 5% CO2.  The day before screening, 
cells were dissociated using cell dissociation 
buffer (Sigma) and split into 384-well Perkin 
Elmer white CulturPlateTM at 8,000 cells per well 
using the Thermo Electron Corporation Mul-
tidrop 384, in plating medium (10% FBS and 1% 
P/S in non-phenol red DMEM).  Compound and 
DMSO control plates were diluted in media and 
transferred to cells using the Beckman Coulter 
Biomek® NX Laboratory Automation Work-
station for a final compound concentration of 
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~1μM in the assay and incubated with cells 
overnight.  Luciferase detection was performed 
using the Perkin Elmer BriteLite Plus Ultra-High 
Sensitivity Luminescence Reporter Gene Assay 
System.  Substrate was added to cells using the 
Biomek® FX Laboratory Automation Work-
station and incubated for 5min in the dark at 
room temperature to allow luminescence to 
reach peak development.  Finally, luminescence 
was measured using the Perkin Elmer EnVi-
sionTM multilabel plate reader.  Any compound 
that lowered luciferase signal  50% than the 
average DMSO control was considered as po-
tential hit.  Potential hits were reviewed by me-
dicinal chemistry to confirm that they do not 
affect luciferase activities. 
 
12-Point dose response assays 
 
Selected compounds were re-ordered and dis-
solved in DMSO to produce 50μM stock solu-
tions and then serially diluted to produce twelve 
different concentrations starting at 50μM final 
in the assay.  Compounds and DMSO control 
were first diluted into 96-well plates and then 
quadmapped into 384-well plates and assayed 
as described above.  
 
Cell toxicity and cell proliferation assays 
 
To assess the effect of compounds on cell toxic-
ity, the Promega CellTiter-Glo Luminescent Cell 
Viability Assay was used in accordance with 
manufacturer’s protocol in parallel with the pri-
mary screening assay.  Cells were plated into 
384-well plates and allowed to settle overnight.  
The next day, 10 μL substrate was added to 
cells for 10min at room temperature, and read 
on the plate reader.  To assess the effect of 
compounds on cell proliferation, the Promega 
CellTiter 96® AQueous Non-Radioactive Cell Prolif-
eration Assay (MTS) was used.  Cells were 
plated in 96 well plates and compounds were 
added to cells the next day.  The following day, 
absorbance was measured following substrate 
addition. 
 
Data analysis 
 
The Graphpad Prism 5 software was used for 
data analysis.  Statistical differences were 
evaluated using the non-parametric Kruskal-
Wallis test, followed by a post-hoc Dunn’s multi-
ple comparison test. For the 12-point dose re-
sponse experiments, data were plotted using a 
non-linear log (inhibitor) vs. response – variable 
slope (four parameters) curve fit to calculate the 
concentration at 50% Inhibition (IC50) values.  
Protein expression in Western blots was ana-
lyzed by densitometry using ImageJ software. 
 
Results 
 
Development of APP-firefly luciferase enzyme 
fragment complementation (APP Fluc EFC) sys-
tem 
 
The APP FLuc EFC system optimized for HTS is 
illustrated in Figure 1. APP tagged to full-length 
luciferase enzyme is represented as APP Fluc 
FL. There is a 13 amino acid linker region 
(STVPRARDPPVAT) between APP and the 
luciferase fragment.  The full-length luciferase 
enzyme is then split into two fragments, one 
corresponding to its N- terminal end with amino 
acids 1-475, and one corresponding to its C-
terminal end with amino acids 265-550.  These 
complementing fragments have been shown to 
produce the most optimal luciferase signal [44].  
When APP is in monomeric form, there is no 
luciferase activity as the luciferase enzyme is 
fragmented.  However, when APP dimerizes, the 
luciferase fragments reconstitute into a fully 
functional active enzyme. Addition of a 
luciferase substrate produces luminescence, 
which allows for the quantification of APP 
dimerization.   
 
Protein expression of APP firefly luciferase con-
structs 
 
Protein expression of the cloned APP Firefly 
luciferase (APP FLuc) constructs in transfected 
HEK293 cells was analyzed by SDS-PAGE fol-
lowed by western blotting.  Figure 2B shows a 
representative blot of the constructs.  When 
cells were transfected with the pcDNA3.1 empty 
vector, no protein bands were detected. When 
cells were transfected with the APP FLuc FL con-
struct, there was a protein band at ~172kDa, 
which corresponds to the 110kDa APP, along 
with the 62 kDa luciferase enzyme.  When cells 
were transfected with the APP FLucN fragment, 
a smaller protein band at ~162kDa was seen, 
as the N-terminal fragment consists of only 475 
amino acids of the full-length luciferase.  When 
cells were transfected with the APP FLucC frag-
ment, an even smaller protein band at ~142 
kDa was seen, as the C-terminal fragment con-
sists of only 285 amino acids of the full-length 
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luciferase.  Finally, when cells were transfected 
with both the APP FLucN and the APP FLucC 
fragments, protein bands corresponding to each 
respective constructs were seen.  Notice that in 
all samples, an additional protein band for the 
immature, non glycosylated, form of APP was 
also seen.  Accordingly, the results show that 
the APP FLuc constructs can be expressed ap-
propriately in HEK293 cells. 
 
Quantification of APP dimerization by measure-
ment of firefly luciferase activity  
 
To test for the functionality of the APP FLuc sys-
tem, luminescence of transfected cell lysates 
was measured in a luciferase assay (Figure 2A).  
Only background luminescence was observed 
for cells transfected with pcDNA3.1, and for 
cells transfected with the APP FLucN or the APP 
FlucC fragments alone.  On the other hand, lu-
minescence significantly higher than back-
ground can be seen from cells transfected with 
APP FLuc FL or co-transfected with both APP 
FLucN and APP FLucC (APP FLuc EFC).  Notice 
that the complemented luciferase activity is 
lower than the full-length luciferase control.  
This is not surprising given that only a portion of 
the APP dimers would result in the correct com-
plementation. Nevertheless, the luminescence 
from the APP FLuc EFC cell lysates corresponds 
to APP forming dimers where luciferase frag-
ments were brought close enough to comple-
ment each other to form an active luciferase 
enzyme.  Thus, the APP FLuc EFC assay can 
readily be used to quantify the amount of APP 
dimerization in cell systems.  After validating the 
use of the APP FLuc EFC system, a stable cell 
line was generated for the APP luciferase con-
structs for HTS. 
 
High throughput screening results 
 
For the HTS, cells stably transfected with the 
APP FLuc EFC fragments were treated with dif-
ferent compounds to assess changes in 
luciferase activity.  A total of 77,440 com-
pounds were screened; of those, 113 com-
pounds lowered luciferase signal 50% or more.  
This amounts to a final hit rate of 0.15%.  Figure 
3A shows the results of ~10,000 representative 
compounds that were tested.  Data points that 
Figure 1. Schematic diagram of the APP-
Firefly luciferase enzyme fragment com-
plementation (APP FLuc EFC) system.  
Deletion mutants of the overlapping 
Firefly luciferase fragments were gener-
ated, where FLucN corresponds to the N
-terminal fragment of luciferase with 
amino acids 1-475, and FLucC corre-
sponds to the C-terminal fragment of 
luciferase with amino acids 265-550.  
APP tagged to full-length Firefly 
luciferase (APP FLuc FL) was con-
structed as a positive control for lumi-
nescence-inducing activity. 
Figure 2. Validation of APP-Firefly luciferase system.  
A. Quantification of APP dimerization by measure-
ment of luminescence.  No luminescence is detected 
from HEK293 cells transfected with pcDNA1, or cells 
transfected with the APP FLucN or APP FLucC frag-
ments alone.  Luminescence is detected only in cells 
transfected with the APP FLuc FL control or cells co-
transfected with both the APP FLucN and APP FLucC 
fragments (APP FLuc EFC).  APP FLuc EFC activity is 
correlated to APP dimerization.  Results shown are 
mean ± standard error, n = 3.  B. Protein expression 
of APP Firefly luciferase constructs.  HEK293 cell 
lysates were ran on 8% Tris-Glycine gel.  Protein sam-
ples in each lane correspond to the luminescence 
samples in Fig. 2A. 6E10 antibody was used at 
1:1000 dilution. 
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fall lower than the mean represent potential 
APP dimerization inhibitors.  Figure 3B shows 
the percent inhibition for each compound from 
Figure 3A. Any compound that inhibited greater 
than 50% inhibition line was considered a po-
tential hit. 
 
12-Point dose response and toxicity assays 
 
12-point dose response experiments were con-
ducted using the APP FLuc assay system to con-
firm the effects of compound treatment on APP 
dimerization and evaluate potency. Since the 
luciferase signal in this assay could be reduced 
if the compounds were toxic to the cells, cell 
viability was tested in parallel to rule out toxic 
compounds.  Of the 113 candidate compounds 
identified in the initial HTS, only 14 of the re-
tested compounds displayed dose-response 
effects and were non-cytotoxic.  Of these 14 
compounds, two compounds, LDN-0128964 
(compound X) and LDN-0004724 (compound 
Y), were selected for further studies based on 
potency and lack of toxicity (Figure 4).  Both 
compounds had IC50 values in the low nM 
range. 
 
Effect of compounds on luciferase activities 
 
The effect of compounds X and Y on luciferase 
activity was analyzed to ensure that the de-
crease in luminescence by the compounds is 
due to inhibiting APP dimerization, and not by 
affecting luciferase activity.  Cells that were 
transiently transfected with luciferase plasmids 
were used.  Figure 5A shows the effects of the 
compounds on luciferase activity as fold change 
compared to DMSO control.  Neither compound 
X nor Y affect luciferase activity and can be 
categorized as novel small molecule APP dimeri-
zation inhibitors.  A corresponding cell prolifera-
tion assay in Figure 5B was used to demon-
Figure 3. Representative results from HTS.  Effects of 
~10,000 compounds on stably transfected APP FLuc 
EFC cells are shown, which represent ~1/7 of the 
total compounds screened.  Each data point repre-
sents a single compound.  A. Luminescence results.  
The mean luciferase signal is about 12,000 RLU.  
Data points that fall lower than the mean represent 
potential APP dimerization inhibitors.  B. Percent (%) 
inhibition as calculated for each compound as com-
pared to DMSO control.  % inhibition is calculated as 
[(Average DMSO signal – Compound Signal)/ Average 
DMSO Signal] x 100.  Only data points that fall over 
the 50% or higher cutoff point are considered as po-
tential hits.  
Figure 4. 12-Point dose response and toxicity curves.  
Representative 12-point dose response and toxicity 
curves for compounds X and Y are shown.  A. The 
dose-response curves demonstrate that increasing 
compound concentration increased inhibition of 
assay signal, which can be correlated to inhibition of 
APP dimerization.  B. In the accompanying toxicity 
curves, the 12 compound doses are shown to be 
non-toxic to cells.  IC50 values are mean ± standard 
deviation, n = 2, in quadruplicates. 
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strate that any differences seen in luciferase 
signal is not due to a change in cell number.   
 
Effect of compounds on Aβ production by ELISA 
 
After validating that the selected compounds do 
inhibit APP dimerization, their effects on Aβ pro-
duction was investigated.  Cells stably trans-
fected with untagged WT APP cells were used.  
After correcting for APP protein expression by 
Western blots, cells treated with compound X 
did not had a significant effect on Aβ production 
as compared to cells that were treated with the 
DMSO vehicle control, while compound Y signifi-
cantly reduced both Aβ40 or Aβ42 levels (Figure 
6A and B).  The Aβ42 to Aβ40 ratios remained 
unchanged for cells treated with either of the 
compounds as compared to DMSO control 
(Figure 6C).  These results are valid for the 1 μM 
concentration at which the compounds were 
tested, where both compounds X and Y maxi-
mally inhibited dimerization at ~70-80%.   
 
Effect of compounds on APP processing  
 
The effects of compounds X and Y on APP pro-
tein expression and APP processing were also 
examined in stably transfected WT APP cells.  
Figure 7 is a representative Western blot of 
treated cells and the expression level of total 
APP; the level of sAPPα, which indicates α-
secretase processing; the level of sAPPβ, which 
indicates β-secretase processing, and the levels 
of the C-terminal fragments (-CTFs), C99 and 
C83, which indicate -secretase processing fol-
lowing β or α secretase, respectively.  The re-
sults indicate that the expression of APP and 
most of its processed products were unaltered 
in the presence of the compounds as compared 
to DMSO control; however, there is a significant 
reduction in sAPPβ release in the presence of 
compound Y.  As there is no change in the C99 
level, this may suggest that compound Y may 
lower Aβ40 and Aβ42 production by altering β-
secretase activity. 
 
Discussion 
 
APP dimerization has been reported by several 
groups to affect Aβ levels.  However, it is un-
clear whether dimerization increases or de-
creases Aβ [8, 13, 32, 38-40].  The methods 
Figure 5. Effect of compounds on luciferase signal.  
A. Dual Luciferase assay.  Compounds X and Y did 
not significantly affect luciferase signal in trans-
fected HEK293 cells as compared to DMSO.  B. 
Cell proliferation assay.  Compounds X and Y did 
not affect cell number in transfected HEK293 cells 
as measured by MTS viability assay .  Results are 
fold changes over DMSO control, mean ± standard 
error, n = 4. 
 
Figure 6. Effects of compounds on Aβ40 and 42 
production.  Aβ was measured from the media of 
stably transfected WT APP cells treated with DMSO 
or with 1 μM of compound X or Y by ELISA.  Aβ 
levels are then normalized to APP protein expres-
sion via densitometry of western blots.  A. Com-
pound X did not significantly affect Aβ40 level as 
compared to DMSO vehicle control, but there is a 
trend towards a decrease.  Compound Y signifi-
cantly reduced Aβ40 with p<0.05.  B. Similarly, 
compound X did not significantly affect Aβ42 as 
compared to DMSO vehicle control, but there is a 
trend towards a decrease. Compound Y signifi-
cantly reduced Aβ42 with p<0.05.  C. Both com-
pounds X and Y did not affect Aβ42 to Aβ40 ratio.  
Results are mean ± standard error, n = 7. 
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used to determine the effects of APP dimeriza-
tion on Aβ generation also vary widely, possibly 
accounting for some of the inconsistencies.   
These approaches include introducing muta-
tions to cross-link monomers into dimers 
(K624C APP) [13], introducing mutations to dis-
rupt dimerization sites (GxxxG mutants) [8, 38, 
39], using complementing peptides to the APP 
growth factor-like domain (GFLD) loop domain 
[32] and the GxxxG motif [48] to block dimer 
formation, analyzing familial APP mutants in 
micelles, phospholipid bilayers [38] and in cellu-
lar systems (So et al., manuscript in prepara-
tion), and inducing dimerization with FKBP, an 
rapamycin analog [40].  In this study, we devel-
oped an additional technique to monitor APP 
dimerization.  An advantage of our APP FLuc 
system is that it eliminates the issue of intro-
ducing mutations that can affect -secretase 
processing.  At the same time, it measures 
dimer formation in cells more naturally as com-
pared to inducing dimer formation with exoge-
nous drugs [40].  The luciferase fragments are 
also small in size, which minimizes interference 
with the normal biological activities of APP.  
Moreover, the complemented APP proteins are 
fully reversible into monomers [43].  A similar 
method using β-galactosidase EFC has previ-
ously been described by our group [49], and 
another method using Renilla luciferase has 
been described by others to monitor APP and -
secretase interactions [50].  One of the most 
important features of luciferase complementa-
tion is that it can be miniaturized and adapted 
to a high-throughput format for drug screening.  
Using this method, we screened a large com-
pound library to identify APP dimerization modu-
lators with the hope to better understand the 
relationship between APP dimerization and Aβ 
production.   
 
Two potent inhibitors,LDN-0128964 (Compound 
X) and LDN-0004724 (Compound Y), were iden-
tified by HTS.  To our knowledge, this is the first 
report of small molecules that can inhibit APP 
dimerization.  The IC50 values of the compounds 
are at a nanomolar range, which signifies their 
potencies.  However, whether these compounds 
prevent de novo APP dimer formation and/or 
break existing dimers apart is unknown.  Fur-
ther evaluation is necessary to fully understand 
the mechanisms of the compounds’ actions.  
We also hypothesized that modulating dimeriza-
tion would affect Aβ production. Whether dimeri-
zation increases or decreases Aβ, our results 
would provide more information as to the rela-
tionship between these two processes.  To our 
surprise, compound X had no significant effect 
on Aβ production, APP protein expression, and 
Figure 7. Effect of compounds on APP processing.  A. 
Cell lysates and media from stably transfected WT 
APP cells treated with DMSO or with 1 μM of com-
pound X or Y were collected and ran on 8% SDS-PAGE 
Tris-Glycine gel followed by western blot.  The repre-
sentative blots indicate the effects of compounds X 
and Y on APP protein expression and the APP proc-
essing products sAPPα, sAPPβ, and the -CTFs, C99 
ad C83.  B. Upon quantification, densitometric plots 
indicate that compound X does not affect APP expres-
sion and its processing products as compared to 
DMSO control.  However, compound Y significantly 
reduced the sAPPβ at p<0.05.  Results are mean ± 
standard error, n = 7.  
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APP processing; however, there is a small trend 
towards decrease in both Aβ40 and 42.  Note 
that the effects of the compound was tested 
only at 1 μM, which according to the 12-point 
dose curves, is at maximum inhibition of ~70-
80%.  It is possible that at different concentra-
tions, a larger effect may be seen.  It is also pos-
sible that significant inhibition may be seen if 
the compound structure were to be optimized 
with medicinal chemistry.  On the other hand, 
compound Y significantly decreased both Aβ40 
and 42 and sAPPβ levels.  Thus, our results add 
further support to the current literature that 
suggests inhibition of APP dimerization inhibits 
Aβ production. In the APP dimerization assay we 
used APPF Luc EFC and X and Y exhibited a 70-
80% inhibition of dimerization, while only com-
pound Y significantly reduced Aβ levels but only 
by 25% when tested by ELISA of Aβ secreted 
from HEK293 cells stably overexpressing 
untagged APP.  The two systems employed are 
very different and that could explain this dis-
crepancy. Nevertheless, a reduction of only 25% 
in Aβ has been shown recently to be enough to 
rapidly revert cognitive dysfunction in an AD 
animal model treated with bexarotene, an oral 
RXR agonist [51]. 
  
Until now, published data have shown promise 
in terms of utilizing APP dimerization as a thera-
peutic target.   For example, APPsα is known to 
be neuroprotective for neurons.  By introducing 
sAPPα to serum-starved neuroblastoma cells, 
there is an increased amount of disrupted APP 
dimers on the cell surface, along with an in-
crease in survival of neurons.  This implies that 
the neuroprotective effects of sAPPα may be the 
result of disrupting APP dimers [31].  Also, the 
G33 residue (Aβ numbering) in the APP GxxxG 
transmembrane domain is the key residue re-
sponsible for the dimerization of APP [39] and 
oligomerization and toxicity of Aβ [52].  When 
designing peptides that complemented the 
GxxxG motif in Aβ40 and 42, the tendency of Aβ 
to form fibrils was reduced, and pre-formed ma-
ture fibrils also depolymerized. These peptides 
were also able to reduce the toxicity of Aβ42 
and increase the survival of cultured rat cortical 
neurons [48].  In addition, -secretase modula-
tors (GSMs) such as some NSAIDS are known to 
inhibit APP processing, lower Aβ production, and 
inhibit Aβ aggregation [53].  It was once thought 
that these GSMs bind to -secretase and pre-
vent its ability to bind to and cleave APP -CTFs 
into Aβ, but when observing photo-labeled 
GSMs fluoroprobes, it was found that they actu-
ally bind to APP and Aβ, and not -secretase 
[52].  Complementary results of surface plas-
mon resonance (SPR) and nuclear magnetic 
resonance (NMR) analysis showed that the Aβ 
lowering NSAIDs bind to the APP-TMS GxxxG 
dimerization motif.  In fact, sulindac sulfide and 
its derivatives destabilized APP TMS dimer in a 
concentration dependent manner, which corre-
lated with the binding strength and Aβ lowering 
activity [54]. Furthermore, introducing muta-
tions at the GxxxG motif in familial APP mutants 
decreased Aβ levels and rescued the effects of 
familial AD.  These results suggest that the APP 
transmembrane dimerization GxxxG motif is not 
only important in WT APP, but also in familial 
APP mutants [55].  Given these data, it seems 
that dimeric APP is a promising drug target that 
could be relevant to both sporadic and early 
onset AD.  Our data further support the notion 
that inhibiting APP dimerization with small mole-
cules can be beneficial by reducing Aβ.  Future 
plans of this study include working with medici-
nal chemistry to modify the chemical structures 
and synthesize analogues of the lead com-
pounds to enhance their ability to further lower 
Aβ levels.  It would also be interesting to exam-
ine whether the APP dimerization activators 
identified in this screen would increase Aβ pro-
duction.  In this study, about 80 compounds 
from the screening library were identified as 
activators that increased the luciferase signal 
50% or more when compared to DMSO controls.  
These compounds could prove to be an addi-
tional set of tool molecules to investigate the 
role of APP dimerization in AD.  In summary, we 
have shown here that modulation of APP dimeri-
zation is a promising therapeutic target for AD; 
however, we also believe that more research in 
regards to the biological significance of APP 
dimers and their impact on Aβ production is 
needed before we can fully exploit this target for 
AD drug discovery.  These new tools are an im-
portant step towards this goal. 
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